Esmo 2021 – Astra finally sees a Wee1 signal
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.
Five Prime looks to turn a corner
Survival data with bemarituzumab see the company erase half of the past three years’ losses.
New Genmab/Abbvie tie-up rings old bells
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.
Esmo 2019 preview – Parps on parade
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
